drugset / Trial / NCT02525094
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
Timeline
- Start
- 2015-08-15
- Primary completion
- 2016-05-09
- Completion
- 2016-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tezepelumab | Monoclonal antibody | 280 mg | Subcutaneous |